Becton, Dickinson and Company has been awarded a $1,798,090 contract for advanced development of a new point-of-care diagnostic test combining detection of influenza virus with identification of antiviral drug resistance in clinical respiratory samples.
The major goal of the contract is to develop a new diagnostic test for identifying influenza antiviral resistance on a combination platform with an FDA-cleared test for detection of influenza A and B.
The award was made under Solicitation Number: BAA-11-100-SOL-00021 by the Office of the Assistant Secretary for Preparedness & Response (ASPR) of the Department of Health and Human Services.
From Our Partners
